`
`
`PAUL
`HASTINGS
`
`Home > Professionals > Evan D. Diamond
`
`EVAN D. DIAMOND
`
`Associate, Litigation Department
`
`New York
`T 1(212) 318-6004
`F 1(212) 230-5104
`
`evandiamond@paulhastings.com
`Download VCard I Download PDF
`
`Evan D. Diamond is an associate in the Life Sciences Intellectual
`Property practice of Paul Hastings. Mr. Diamond's practice focuses
`on patent litigation matters in the fields of pharmaceuticals and
`biotechnology. Mr. Diamond has represented clients in federal
`district court litigations, in appeal proceedings before the Federal
`Circuit, and in inter partes review proceedings before the Patent
`Trials and Appeals Board. In addition, Mr. Diamond has provided
`strategic counseling to clients regarding potential litigation and
`other patent-related matters.
`
`Experience
`
`Galderma Laboratories, L.P. and Supernus
`Pharmaceuticals, Inc.: Patent infringement litigation relating
`to the rosacea treatment Oracea®. Successfully upheld
`validity of longest-running patent covering Oracea® in federal
`district court, followed by a per curiam affirmance by the
`Federal Circuit. Successfully obtained preliminary injunction
`precluding generic launch prior to patent expiration. Continued
`to defend against subsequent challenges to patents covering
`Oracea® in federal district court and in inter partes review
`proceedings.
`
`Eisai Inc.: Patent infringement litigation regarding
`Targretin®, a treatment for cutaneous T-cell lymphoma.
`
`Forest Laboratories, Inc. and Merz Pharmaceuticals
`GmbH: Patent infringement litigation relating to Alzheimer's
`disease treatment Namenda®.
`
`PRACTICE AREAS
`
`Litigation
`
`Life Sciences
`
`Patent Office
`
`Patent Litigation
`
`Intellectual Property
`
`ADMISSIONS
`
`New York Bar
`
`EDUCATION
`
`Harvard Law School,
`ID., 2007
`University of
`Pennsylvania, B.A.,
`2004
`University of
`Pennsylvania, M.S.,
`2004
`
`NEWS
`
`Paul Hastings Achieves
`First Ever Win in New
`Form of IP Proceeding
`for Pharmaceutical
`Company
`
`December 11, 2014
`
`INSIGHTS
`
`Paul Hastings Wins for
`Galderma and Supernus
`in First Hatch-Waxman
`Inter Partes Reviews to
`Reach Final Written
`Decision
`
`December 10, 2014
`
`Friday, September 11, 2015 (cid:9)
`
`Page 1 of 2
`
`Galderma Laboratories, Inc., Ex. 2002
`Dr. Reddy’s Labs. V. Galderma Labs., Inc.
`IPR2015-01782
`
`000001
`
`
`
`http://www.paulhastings.com/professionals/details/evandiarnond
`
`Forest Laboratories, Inc. and H. Lundbeck A/S: Patent
`infringement litigation concerning the multi-billion dollar drug
`product Lexapro®, a selective serotonin reuptake inhibitor
`indicated for the treatment of depression and anxiety.
`
`Accolades and Recognitions
`
`Financial Times, U.S. Innovative Lawyers 2012: top "Standout"
`rating in Intellectual Property awarded to Paul Hastings for
`representation of Galderma in Oraceag litigation
`
`FDA Issues Draft
`Guidance on Reference
`Product Exclusivity for
`Biologics
`
`August 07, 2014
`
`Paul Hastings Wins
`Federal Circuit
`Affirmance Upholding
`Key Patent Covering
`Once-Daily Formulation
`for ORACEA
`
`Law360, Life Sciences Group of the Year (2013), awarded to
`Paul Hastings for representations including Galderma in
`Oraceag litigation
`
`Honorable Mention, H. Thomas Austern Memorial Writing
`Competition, Food and Drug Law Institute (2008)
`
`August 09, 2013
`
`Read More [1-/-]
`
`RANKINGS &
`AWARDS
`
`Speaking Engagements and Publications
`
`Panelist, "Predictions Related to Biosimilars
`Challenges" (NewYorkBIO Conference, May 2014)
`
`E. Diamond, "Reverse-FOIA Limitations on Agency Actions to
`Disclose Human Gene Therapy Clinical Data," 63 Food & Drug
`L. 3. 321 (2008)
`
`G.S. Pesiridis, E. Diamond, and G.D. Van Duyne, "Role of pICIn
`in Methylation of Sm Proteins by PRMT5," J. Biol. Chem. (2009)
`284:21347-21359
`
`Education
`
`Harvard Law School, J.D. (cum laude), 2007
`
`University of Pennsylvania, B.A. in Biochemistry (summa cum
`laude, Phi Beta Kappa), 2004
`
`University of Pennsylvania, M.S. in Chemistry, 2004
`
`Legal Media Group's
`2013 LMG Life
`Science Awards
`The firm was nominated
`as a 2013 LMG Life
`Science nominee in the
`"Litigation Team of the
`Year" and "(General)
`Patent Litigation: Firm
`of the Year" categories.
`
`August 12, 2013
`
`Intellectual
`Property
`
`Intellectual Property
`Magazine
`Intellectual Property
`Magazine recognized
`Paul Hastings' IP
`Pharmaceutical Team as
`the Pharmaceutical
`Team of the Year.
`
`November 30, 2010
`
`At
`
`P
`
`Friday, September 1 1, 2015 (cid:9)
`
`p,2e 2 of 2
`
`Galderma Laboratories, Inc., Ex. 2002
`Dr. Reddy’s Labs. V. Galderma Labs., Inc.
`IPR2015-01782
`
`000002
`
`(cid:9)